key: cord-0275493-a551mx6r
authors: Sondergaard, J.; Tulyeu, J.; Edahiro, R.; Shira, Y.; Yamaguchi, Y.; Murakami, T.; Morita, T.; Kato, Y.; Hirata, H.; Takeda, Y.; Okuzaki, D.; Sakaguchi, S.; Kumanogoh, A.; Okada, Y.; Wing, J.
title: Regulatory T-cells are central hubs for age-, sex- and severity-associated cellular networks during COVID-19
date: 2022-01-06
journal: nan
DOI: 10.1101/2022.01.06.22268711
sha: 17738437cd6ed326d70e3529eed2c5a5012d06a0
doc_id: 275493
cord_uid: a551mx6r

Using single-cell proteomics by mass cytometry, we investigate changes to a broad selection of over 10,000,000 immune cells in a cohort of moderate, severe, and critical Japanese COVID-19 patients and healthy controls with a particular focus on regulatory T-cells (Tregs). We find significant disruption within all compartments of the immune system and the emergence of atypical CTLA-4high CD4 T-cells and proliferating HLA-DRlowCD38high Tregs associated with critical patients. We also observed disrupted regulation of humoral immunity in COVID-19, with a loss of circulating T follicular regulatory T cells (Tfr) and altered T follicular helper (Tfh)/Tfr and plasma cell/Tfr ratios, all of which are significantly lower in male patients. Shifting ratios of CXCR4 and CXCR5 expression in B-cells provides further evidence of an autoimmune phenotype and dysregulated humoral immunity. These results suggest that Tregs are central to the changing cellular networks of a wide range of cells in COVID-19 and that sex specific differences to the balance of Tfr, Tfh and plasma cells may have important implications for the specificity of the humoral immune response to SARS-CoV-2.

Since the initial outbreak in late 2019 1 the devastating SARS-CoV-2 pandemic and the associated COVID-19 disease have had a severe impact on the global community, making it essential that we understand this disease in greater detail. Susceptibility to infection appears to be driven by a range of factors, with risk increasing particularly with age and, to a lesser extent, male sex 2 . Understanding the changes to the immune system of infected patients is imperative since both viral clearance and many acute symptoms are mediated by the immune system 3, 4 . Several previous studies have analyzed the immune response during COVID-19 and demonstrated significant dysregulation of almost every immune population [5] [6] [7] [8] . This is also true for regulatory Tcells (Tregs), with several groups having reported some degree of disruption in their frequency, although a clear consensus has yet to emerge 9, 10 .

Foxp3 expressing Tregs play a key role in the control of the immune system due to their ability to suppress the function of a wide range of cell types and prevent severe autoimmunity 11 . Tregs are also known to dampen the resolution phase of an infection and have been demonstrated to have an important role in the response to various infectious diseases such as influenza and malaria 12, 13 . Of particular relevance in the context of viral lung infections is the role of the specialized Treg subset T follicular regulatory T cells (Tfr) to control plasma cell formation, the quality of the specific antibodies, emergence of autoreactive antibodies, B-cell memory, and protection from lung damage during influenza infection [14] [15] [16] . Several recent reports 17, 18 have demonstrated that many patients with COVID-19 produce autoantibodies, which may have a critical role in the progress of infection due to their ability to neutralize protective host factors such as Interferons. In some cases, these autoantibodies are a pre-existing risk factor prior to infection. However, there is also clear evidence of de novo generation 19 . These factors suggest that Tregs and Tfr may be an important factor in understanding both susceptibility to, and recovery from, COVID-19.

Considering these prior findings, we hypothesized that Tregs may have potential roles both in the acute anti-viral response and the development of post-infection autoimmunity in COVID-19. In this report, we leverage the ability of single-cell proteomics (mass cytometry) to resolve rare populations, such as Treg subsets, while also retaining a broad view of the immune system in a large patient cohort. We find that subsets of Tregs are key parts of the changing cellular networks related to severity, age, and sex of patients. Most notably, we see that patients with COVID-19 have a reduced ratio of Tfr to both T follicular helper (Tfh) and antibody producing plasma cells, and that this is more severe in male patients. Our data provides cellular evidence of dysregulated antibody responses, which could explain previous reports of increased autoantibodies in male patients.

Peripheral blood mononuclear cells (PBMCs) from 40 healthy controls and 55 COVID-19 patients ( Table 1) were labelled with metal-tagged antibodies and analyzed on a Helios mass cytometer (Fig. 1) . Self-organizing map (FlowSOM) clustering of CD45 + live cells showed clear resolution of most major immune subsets (Extended data Fig.1A) .

Analysis of changes to cellular frequency demonstrate that in comparison to healthy controls, severe COVID-19 patients had significantly increased frequencies of B-cells, plasma blast cells (plasma), and classical monocytes (cMono) (Extended data Fig.1B and 1C). In contrast, CD8 T-cells, non-classical monocytes (ncMono), conventional dendritic cells (cDCs), and plasmacytoid dendritic cells (pDCs) were all significantly reduced in a manner similar to previous reports 7, 8 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 6, 2022. In-depth sub-clustering of CD4 T-cells identified a range of previously described CD4 Tcell populations that we manually annotated based on examination of Uniform manifold approximation and projection (UMAP) distribution and expression of markers used for clustering ( Fig. 2A) . For example, central memory (CM) cells were identified as CD95 + CCR7 + CD45RAcells located between the naïve and effector memory areas of the UMAP, while granzyme B + cytotoxic CD4 T-cells (annotated as GZMB + CTL) were identified as CD95 + CD57 + GZMB + ( Fig. 2A) . Changes to the proportions of clusters in COVID-19 revealed perturbations across the spectrum of naïve to effector cells (Fig.   2B, 2C) . Expansion of several groups of proliferative Ki67 + CD4 cells was seen including a group of less differentiated Ki67 lo cells that retained TCF1 and CCR7 (annotated as Ki67 lo ) and two more terminally differentiated HLA-DR + (HLA-DR + Ki67 + ) and CXCR3 + (Ki67 + Th1) subgroups mostly lacking markers of stemness such as TCF1 20 . Nonproliferating CXCR3 + cells (Th1) were reduced in the COVID-19 patients, potentially as they had shifted to the Ki67 + Th1 group (Fig. 2B) . Interestingly, we observed that the Ki67 + Th1 cluster was significantly higher in critical than severe patients (Fig. 2B, 2C) and showed extremely high levels of intracellular CTLA-4 ( Fig. 2A, 2D) . While CTLA-4 is not exclusively expressed by Tregs, in both healthy donor PBMCs and most highly activated environments such as tumors, effector Tregs reliably express higher levels of CTLA-4 than all other populations of effector CD4 and CD8 21 . However, in this case the Ki67 + Th1 cluster had significantly higher CTLA-4 expression than even effector Tregs is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 6, 2022. ; https://doi.org/10.1101/2022.01.06.22268711 doi: medRxiv preprint parallel to Tregs due to their relative phenotypic similarity (Extended data Fig.2A, 2B) . A significant shift in clusters within phenotypically naïve CD4 cells was also observed. This was primarily characterized by increased expression of CXCR4, the chemokine receptor for CXCL12, and a resulting shift in the frequency of clusters from CXCR4 lo naïve to CXCR4 hi naïve in moderate, severe, and critical COVID-19 patients and then returned to CXCR4 lo naïve in follow-up samples (Fig. 2B, 2C, 2D) . These CXCR4 hi naïve cells retained expression of CD45RA, CD27, CD127, TCF1 and CCR7 but close examination indicated slight changes to the expression of some markers ( Fig. 2A) , suggesting a later stage of development. To confirm this, we verified that the CXCR4 hi naïve cluster had significantly reduced expression of the recent thymic emigrant marker CD31 (Extended data Fig.1C ). Significant but low upregulation of CD95 was also seen (Extended data Fig.1D) , suggesting a phenotypic similarity with CD95 + CD45RA + Tstem memory (TSM) cells 23 . However, since most naïve cells in COVID-19 patients gain this phenotype, we consider it unlikely that this is driven by antigen-specific memory development but rather that CXCR4 may prime naïve T-cells for trafficking to the lungs of COVID-19 patients 24 .

Several reports on COVID-19 have demonstrated some degree of disruption in Tregs 9 .

We saw that Tregs as a proportion of CD4 were not changed in acute COVID-19 but appeared to be reduced at the follow-up stage (Fig. 2F) . Additionally, some shift from naïve to effector Tregs was clear at the CD4 level ( Fig. 2A, B) . Tregs are a complex population with a range of known subtypes 25 . To gain a better resolution of their subphenotypes, we performed sub-clustering of Tregs (Fig. 3A) . While there is no true . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 6, 2022. (Fig. 3A, 3B) . A shift towards activated Treg subtypes was seen in patients with COVID-19 with increases in the activated CCR4 + (annotated as CCR4 + ), Helios -CCR6 + effectors, and several groups of proliferating Tregs.

( Fig. 3C, 3D) . A corresponding reduction in the proportions of naïve, Tfr and CM-like was observed. The proliferating Helioscluster (Ki67 + Helios -) lacked any clear association with COVID-19, while the Ki67 + HLA-DR + cluster was generally increased in all COVID-19 patient groups. However, the CD38 hi HLA-DRgroup of proliferating Tregs (Ki67 + CD38 + ) was significantly increased in critical patients in comparison to severe or moderate groups (Fig. 3D, 3E) , suggesting an association with the most severe forms of the disease.

We also performed re-clustering of NK, CD8, B-cells, and myeloid cells and were able to replicate key findings from previous literature, demonstrating the accuracy of this analysis. Severe COVID-19 infection led to increased proportions of activated, proliferating and cytotoxic CD57 + CD69 + and Ki67 + NK cells while Granzyme-B lo CD57 -NK and CD56 hi CD16 lo NK were decreased (Extended data Fig.3A -E) 32 . In CD8 T cells, naïve and CD161 + CCR6 + mucosal associated innate T-cells (MAIT) were greatly reduced while several subgroups of proliferating Ki67 + effector memory like cells characterized by high expression of both CD38 and HLA-DR were increased (Extended data is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 6, 2022. ; https://doi.org/10.1101/2022.01.06.22268711 doi: medRxiv preprint were generally reduced (Extended data Fig.6A-E) . Since we collected information on many cell types, we next sought to use this information to determine the associations between these changing cellular populations by correlation analysis. To avoid undue influence from larger populations, such as cMono, we used subset frequencies within each level of clustering rather than as a proportion of all cells. For example, Treg: naïve is the proportion of the naïve Tregs as proportion of all Tregs. A large network of cells correlating with each other was increased in COVID-19, including groups of proliferating, or activated CD4, CD8, Treg, B-cells, plasma cells, NK (CD69 + ), and cMono. (Fig. 4A) . We also visualized these changes as networks to enable a better understanding of the relationships between cells (Extended data Fig.7) . Highly proliferating Tregs were seen to be in close correlation with plasma cells and HLA-DR lo cMono and the Ki67 + Th1 cluster of CD4 T-cells. Cellular groups that were decreased in COVID-19 patients included several types of less activated Tregs (Tfr, naïve and CMlike) in correlation with groups of DCs (pDC and cDC), CXCR4 lo naïve CD4, naïve CD8, and CD56 hi CD16 lo NK cells and monocyte subgroups (intermediate, non-classical and HLA-DR hi cMono). Overall, these results suggest a general shift to dysfunctional and suppressive phenotypes characterized by loss of HLA-DR on monocytes and high levels of suppressive molecules such as CD38 and CTLA-4 expressed by hyperactivated CD4, CD8 and Tregs (Fig. 4A) . While this analysis revealed broad differences between healthy and COVID-19 patients, it could not clearly show differences within patient subgroups (moderate, severe, and critical patients). To further examine this, we used the same approach but excluded healthy and follow-up samples and restricted visualization of the correlation matrix (Extended data Fig.8A ) to the top 5 correlations with moderate and critical patients and the level of positive correlation between these cell types. Moderate patients were associated with several populations that were also correlated with healthy controls such as naïve Tregs, CD73 + memory B-cells, and HLA-DR hi cMono (Fig. 4B) . This likely reflects that the moderate patients are at an intermediate phenotype between healthy controls and more severe patient groups.

Upon examination of associations with the critical patient group, we saw that CD38 + Ki67 + Tregs appears to be a central hub around which dysfunctional HLA- is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 6, 2022. ; https://doi.org/10.1101/2022.01.06.22268711 doi: medRxiv preprint DR lo Ki67 lo cMono, plasma cells, CD11c + CXCR5 -B-cells, and Ki67 + proliferating memory B-cells were organized (Fig. 4B) .

Since age is a major factor for susceptibility to COVID-19 2,37 , we sought to examine the relationship between age and cellular populations. Interestingly, Helios -CCR6 + Tregs were expanded in older COVID-19 patients (Fig. 5A, 5B) . In humans, Helios negativity and expression of CCR6 is characteristic of unstable Tregs capable of producing IL-17 28, 29 . This suggests that while Tregs are generally highly activated in COVID-19, a potentially unstable subpopulation emerges in older COVID-19 patients. The CXCR4 hi naïve T-cell subgroup was also increased with age in COVID-19 patients (Fig. 5A, 5C ).

Since we had observed increased CXCR4 expression by CD4 T cells from COVID-19 patients, we examined its expression on other cell types. In addition to the expected increase in CD4 T-cells, CXCR4 was also upregulated by CD8 T cells, B cells, cDCs, ncMono and NK cells in severe patients, and slightly decreased on cMono (Fig. 5D, 5E ).

These changes in CXCR4 thus appeared to be highly coordinated between cell types.

The balance between CXCR4 and CXCR5 in B-cells is believed to play a key role in autoimmune disorders such as Systemic lupus erythematosus (SLE) and Rheumatoid arthritis, demonstrated by increases in a CXCR4 + CXCR5 lo subset in SLE 38-40 . We observed downregulation of CXCR5 expression by non-plasma B-cells in severe COVID-19 patients (Fig. 5F) , and a greater proportion of CXCR4 + CXCR5 lo B-cells, similar to those previously seen in SLE (Fig. 5G) . These cells were distinct from the CD11c + CXCR5cells that we had found by clustering analysis, which lack CXCR4 expression (Extended data Fig.6A ). The balance of CXCR5 and CXCR4 also has an important role in Tfh localization within germinal centers 41 , and Tfh CXCR5 was reduced in severe COVID-19 patients while CXCR4 was increased (Fig. 5H) . Tfh expression of CXCR4 in COVID-19 patients was also positively correlated with age (Spearman rho = 0.577, p<0.001), while CXCR5 expression was unaffected by age (rho -0.2, p=0.13). is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 6, 2022. ; https://doi.org/10.1101/2022.01.06.22268711 doi: medRxiv preprint Given the known importance of sex in susceptibility to COVID-19 2,37 we then sought to further dissect the associations of sex in our cohort. Since we were aware of sex bias in the critical patient group (Table 1) , we restricted correlation analysis only to the severe patient group (Extended data Fig.8B ) to avoid confounding effects. Female patients showed an overall increase in the proportion of B-cells (Fig. 6B) , as also seen by Takahashi et al. 42 . Plasma cells and Ki67 + CD38 + Tregs were associated with male patients, while the top correlation with female sex was the proportion of circulating Tfr ( Fig. 6A and 6B) . Since a primary role of Tfr is the control of plasma cell formation 15, 16 this suggested a causative link between the inverse relationship of Tfr and plasma cells amongst the sexes. Upon further examination, we found that the proportion of circulating Tfr was reduced as a proportion of Tregs. Similarly, Plasma cells were also significantly reduced in females (Fig. 6B) . Interestingly we also saw that healthy control females had an increased proportion of Tfr (p=0.007) compared to males and that percentages Tfr of Tregs was increased in an age-associated manner in female (rho= 0.569, p=0.01) but not male (rho=0.274, p=0.4) healthy controls. We also observed significant negative correlations between Tfr and plasma cells or Tfr and CD11c + CXCR5 -B-cells within severe patients (Extended data Fig.8B) . Further division by sex demonstrated that the negative correlation of Tfr and plasma cells was significant in female but not male patients, while the Tfr/CD11c + CXCR5 -B-cell negative correlation was significant in both sexes but stronger in females (Fig. 6C) .

While the loss of Tfr is associated with dysregulated control of antibody responses, we also noted a positive correlation between Tfr and Tfh proportions (Fig. 6A) . Previous studies have demonstrated that the balance between Tfh/Tfr and plasma cell/Tfr is more predictive of dysregulated antibody responses than their individual proportions 27,43 . We also examined these ratios in COVID-19 more generally and found that their disruption is apparent in almost all moderate, severe, and critical COVID-19 patients ( Fig. 6D) . Within severe COVID-19 patients, we also found that the ratio of both Tfh/Tfr and plasma cell/Tfr were significantly different between male and female patients (Fig.   6E ). These findings suggest that disruption of Tfr function is a general factor in COVID- is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 6, 2022. ; https://doi.org/10.1101/2022.01.06.22268711 doi: medRxiv preprint 19 that is further exaggerated in male patients. Together with the earlier observed disruptions to CXCR4 and CXCR5 expression in B-cells this suggests a broader picture of dysregulated antibody production during COVID-19.

In summary, analysis of this cohort of COVID-19 patients has pinpointed potentially crucial roles that Tregs may play in organizing multiple aspects of the immune response in COVID-19.

Using mass cytometry to measure broad changes to cellular phenotypes in a large COVID-19 patient cohort, we found a great number of changes, which recapitulated the findings of a number of papers, including abnormal monocytes, highly activated NK, and CD8 cells, acting as both confirmation of previous results and demonstration of the accuracy of our analysis 7, 8, [32] [33] [34] [35] . We also closely examined the status of Tregs during COVID-19. Several papers have observed changes to Treg during COVID-19 9 variously reporting increases, decreases, or no change in Treg frequency. Alongside differences in patient cohorts, a possible cause of this variability is that not all studies use Foxp3 as part of their identification strategy and instead rely on CD127 and CD25.

Since CD25 upregulation and CD127 downregulation are relatively common in highly activated non-Tregs, we would urge significant caution in reliance on surface markers alone to identify Tregs in the blood of patients with COVID-19. Additionally, Foxp3 alone is not always sufficient to correctly identify Tregs 22 suggesting that a range of markers and higher dimensional approaches are needed to fully separate Tregs from non-Tregs in the context of the aggressive cellular activation seen in COVID-19. In our hands, we did not see a clear change in overall Treg frequency, but in agreement with several other studies, a shift from naïve to effector Tregs was observed 10, 44 . We is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 6, 2022. ; https://doi.org/10.1101/2022.01.06.22268711 doi: medRxiv preprint

Here we show that while there is a general increase in activated and proliferating Treg populations, the CD38 hi HLA-DR lo KI67 + subpopulation showed a clear stepwise increase in frequency between moderate, severe, and critical patients. CD38 lo HLA-DR hi KI67 + Tregs were also increased in all patient groups but lacked a clear association with severity. HLA-DR hi Tregs are a known population with high suppressive activity 31 whereas CD38 hi Tregs are a population that have been studied most often in the context of multiple myeloma 45,46 . Furthermore, CD38 hi Tregs from either myeloma patients or healthy donors have increased suppressive function and CD38 blocking antibodies are able to reduce their function 45,46 . In the context of COVID-19, CD38 expression is widely induced across CD8, CD4, Treg, and plasma cells, suggesting that CD38 expression across these disparate populations may either be driven by a central factor or interaction between these cell types. In addition to Tregs themselves, we also is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 6, 2022. Tfr has been demonstrated to control autoantibody production in mice 50 and in humans, reduced circulating Tfr or an increased ratio of Tfh to Tfr are associated with autoantibodies and the frequency of plasma cells in patients 51-54 . In acute COVID-19, we saw that Tfr were reduced, in keeping with another report 55 . There is also evidence that this disruption is prolonged as COVID-19 convalescent patients have a decreased proportion of circulating Tfr and an increased proportion of activated Tfh 56 . We found that Tfr cells were more frequent in female patients and that both the plasma cell/Tfr ratio and the Tfh/Tfr ratio was significantly higher in male COVID-19 patients. This may partly underly the finding that male patients were disproportionately over-represented amongst those with detectable autoantibodies 18 . In the context of infection with respiratory viruses, murine models of influenza have demonstrated that without Tfr, the germinal center becomes dysregulated leading to increased proportions of antigen non-specific B-cells, increased export of plasma cells, and autoreactive antibodies 15, 16 . Further reinforcing this impression of dysregulated humoral immunity, we saw increased CXCR4 expression, a common feature of autoantibody mediated is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 6, 2022. CXCR4 upregulation in CD4 and CD8 cells in PBMCs from COVID-19 patients was also observed in an earlier study, although its distribution across sub-populations or other cell types was not reported 33 . Here we find that this upregulation of CXCR4 is also generalized across many immune cell types of both myeloid and lymphoid origins, suggesting that a global factor is driving CXCR4 expression across a range of subsets in an antigen-independent manner. In addition to its role in extrafollicular B-cell responses, CXCR4 is important in the control of cellular migration to several tissues, most notably the lungs 24 . Most immune cell types present in the bronchoalveolar lavage of COVID-19 patients express high levels of CXCR4 62 . CXCR4 + CD69 + bystander CD4 and CD8 T-cells are seen to increase in the lungs of patients with COVID-19 and lack the tissue-resident marker CD103, suggesting recent infiltration from the periphery 63 . We speculate that the CXCR4 hi naïve CD4 cells in the blood observed here, which lack CD69 expression, may be primed for non-antigen specific infiltration into the lungs and their increased frequency in older COVID-19 patients may play a role in their greater susceptibility to disease. Interestingly, CXCR4 expressing naïve CD4 Tcells are also induced in a murine model of polymicrobial sepsis, and mortality is significantly reduced by blockade of CXCR4 in that setting 64 . Furthermore, CXCR4

signaling blocks production of IFN-I from influenza infected PBMCs, PBMCs from SLE patients, and PBMCs from COVID-19 patients [65] [66] [67] . These findings collectively make the . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 6, 2022. ; https://doi.org/10.1101/2022.01.06.22268711 doi: medRxiv preprint case that dysfunctional cellular migration, inflammation, and autoantibody production in COVID-19 may be targetable via CXCR4. Steroids are also known to induce both CXCR4 expression and changes to CXCR4 signaling via Lck 68 . Since a high proportion of COVID-19 patients, and all patients in this study, are treated with steroids, some consideration of the effect of these drugs on CXCR4 and the relative importance of CXCR4 expression to the efficacy of these drugs in the context of COVID-19 patients is required.

In summation, in all cases, Treg subgroups were central parts of the top 5 most severity-associated (Ki67 + CD38 + : critical COVID-19, naïve Tregs and CM-like Treg: moderate COVID-19), age-associated (Helios -CCR6 + : older patients) or sex-associated 

PBMC samples were collected from a cohort of COVID-19 patients and healthy controls ( is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 6, 2022. antibodies were conjugated with cisplatin as previously described 70 . Conjugated antibodies were stored in PBS-based antibody stabilizer or HRP-protector stabilizer for cadmium labelling (Candor Biosciences). All antibodies were titrated for optimal staining concentrations using control PBMCs.

A total of 9 separate experiments were performed. In each experiment, up to 1.5 × 10 6 cells per sample were labeled with a six choose-two pattern of anti-CD45 barcodes (113In, 115In, 194Pt, 195Pt, 196Pt and 198Pt) is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 6, 2022. ; https://doi.org/10.1101/2022.01.06.22268711 doi: medRxiv preprint stained for viability with dichloro-(ethylenediamine) palladium (II) (DCED palladium, (Table S1C) 71 in PBS for 5 min at RT washed and then fixed and permeabilized using the Foxp3 Transcription Factor Staining Buffer Set according to the manufacturer's protocol (eBioscience). Cells were subsequently stained with a metal-conjugated intracellular antibody cocktail for 45 min at 4 °C (Table S1D) and then washed twice in CyFACS buffer and once in PBS. Cells were then fixed overnight in 1.6% formaldehyde solution containing DNA Cell-ID Intercalator-103Rh (Fluidigm). While DCED palladium contains approximately 11% 110Pd, we find this does not adversely affect resolution of 110Cd based CD3 staining in live cells.

Prior to data acquisition, cells were washed once in CyFACS buffer and twice in MilliQ H2O. Barcoded samples were split into separate tubes of up to 2×10 6 cells, and centrifuged, the supernatant was removed, and samples were left as pellets until shortly before running each tube. Cells were then diluted to 1×10 6 cells/mL in Milli-Q H2O containing 15% EQ Four Element Calibration Beads (Fluidigm) and passed through a 35μm filter immediately before running. Cells were acquired at a rate of 200 to 300 cells/s using a Helios mass cytometer (Fluidigm). Flow Cytometry Standard (FCS) files were normalized to EQ bead signals by the Fluidigm normalizer software. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 6, 2022. ; https://doi.org/10.1101/2022.01.06.22268711 doi: medRxiv preprint cells per sample was used for analysis. Following these data filtering steps, a median of 100,943 (minimum of 18,000) cells per sample were used with a total dataset size of 10,013,285 live CD45 + singlets (Fig. 1A) .

All dual count data channels were arcsinh-transformed (co-factor: 5) then compensated by the CATALYST R package preprocessing workflow (1.14.0) 72 in R of interest (such as CD4 T-cells) from the CD45 + dataset were selected and separately processed by the same analysis workflow. CD8 cells were subject to a further round of filtering using TCRα/β and CD56 to separate them from TCRα/βor CD56 + cells presumed to be gamma delta T-cells and NKT that initially clustered together with CD8 in the first round of analysis. For each analysis of separate subpopulations (CD4, CD8, B-cells etc.) markers used as the basis for clustering "type markers" 73 were altered to select for those with a clear dynamic range of expression or biological interpretability and maximize signal to noise by exclusion of irrelevant markers. All "type markers" are displayed in expression heatmaps ( Fig. 2A, 3A, S1A, S3A, S4A, S5A and S6A) . Markers is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 6, 2022. ; https://doi.org/10.1101/2022.01.06.22268711 doi: medRxiv preprint displayed in expression heatmaps were trimmed to the 99% percentile of each marker, scaled and then aggregated, preserving both information about expression differences between markers and between clusters 73 . For dimensionality reduction samples were down-sampled to a maximum of 1000 cells per sample. UMAP was performed with nearest neighbors set to 15 with the exceptions of the CD8 and NK UMAPs which were set to 20 and 25 respectively for clearer plotting. Markers displayed in UMAPs were trimmed to the 99% percentile and then scaled. Contours were added by ggplot2 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 6, 2022. ; https://doi.org/10.1101/2022.01.06.22268711 doi: medRxiv preprint analysis of correlations used two-sided Spearman rank. Line graphs and Spearman correlation analysis in Fig. 5B, 5C and 6C were performed in GraphPad prism (9.2).

Lines are linear correlation.

Network diagrams of correlations were produced in Gephi software (0.9.2). For the purposes of easier visual display, the negative correlations to the central nodes (COVID score, age, or sex score) were converted to positive values (x*-1). Only positive correlations between cell types were retained. In 

Extended data Fig.1 . Alterations to frequency of CD45 + cells. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 6, 2022. ; https://doi.org/10.1101/2022.01.06.22268711 doi: medRxiv preprint Extended data Fig.6. B-cell and plasma cell phenotypes in COVID-19 . Fig.7 . Broad changes to cellular networks in COVID-19. Fig.8 . Cellular correlations in patient subgroups. Table S1 . Mass cytometry staining panels.

. CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 6, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 6, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 6, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 6, 2022. 

The authors declare no competing interests.

Mass cytometry data is uploaded to flow repository ID: FR-FCM-Z4XN and will be made publicly available upon publication. R code is available on request.

. CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 6, 2022. ; https://doi.org/10.1101/2022.01.06.22268711 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 6, 2022. ; https://doi.org/10.1101/2022.01.06.22268711 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 6, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 6, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 6, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 6, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 6, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 6, 2022. ; https://doi.org/10.1101/2022.01.06.22268711 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 6, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 6, 2022. ; https://doi.org/10.1101/2022.01.06.22268711 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 6, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 6, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 6, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 6, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 6, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 6, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 6, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 6, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 6, 2022. ; https://doi.org/10.1101/2022.01.06.22268711 doi: medRxiv preprint

Healthy controls under 50 years of age (HC<50), healthy control of 50 or over (HC50+), moderate, severe, critical or follow-up COVID-19 patients. E) Comparison of the fold change (log2) in cluster-frequency between the indicated group and severe COVID-19

patients. *p≤0.05, **p≤0.01, **p≤0.001 by edgeR. Fig.7 . Broad changes to cellular networks in COVID-19. Spearman correlation network of cellular subset frequencies between indicated subsets, COVID score (0 = healthy, 1 = COVID-19 patient) and sex (1 = male, 2= female). Edge width is proportional to correlation strength, node size is proportional to the number of connecting edges. Edges connecting to other cellular subsets are positive correlations between indicated subsets. Layout by ForceAtlas2 using edge weights as input.

. CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 6, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 6, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 6, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 6, 2022. . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 6, 2022. ; https://doi.org/10.1101/2022.01.06.22268711 doi: medRxiv preprint

A new coronavirus associated with human respiratory disease in China

Susceptibility to severe COVID-19

Severe Covid-19

Mild or Moderate Covid-19

High levels of SARS-CoV-2-specific T cells with restricted functionality in severe courses of COVID-19

T-Cell Hyperactivation and Paralysis in Severe COVID-19 Infection Revealed by Single-Cell Analysis

Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19

Severe COVID-19 Is Marked by a Dysregulated Myeloid Cell Compartment

Toward an understanding of regulatory T cells in COVID-19: A systematic review

Profound Treg perturbations correlate with COVID-19 severity

Regulatory T Cells and Human Disease

The Yin and Yang of regulatory T cells in infectious diseases and avenues to target them

Control of foreign Ag-specific Ab responses by Treg and Tfr

A Distinct Function of Regulatory T Cells in Tissue Protection

CD4+ follicular regulatory T cells optimize the influenza virus-specific B cell response

Dynamic regulation of T follicular regulatory cell responses by interleukin 2 during influenza infection

Diverse functional autoantibodies in patients with COVID-19

B cell priming for extrafollicular antibody responses requires Bcl-6 expression by T cells

Class-Switch Recombination Occurs Infrequently in Germinal Centers

Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications

Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19

Distinctive features of SARS-CoV-2-specific T cells predict recovery from severe COVID-19

CXCR4 blockade decreases CD4+ T cell exhaustion and improves survival in a murine model of polymicrobial sepsis

Natural amines inhibit activation of human plasmacytoid dendritic cells through CXCR4 engagement

Control of TLR7-mediated type I IFN signaling in pDCs through CXCR4 engagement-A new target for lupus treatment

Targeting the chemokine receptor CXCR4 with histamine analogue to reduce inflammation in juvenile arthritis: a proof of concept for COVID-19 therapeutic approach

Dexamethasone augments CXCR4-mediated signaling in resting human T cells via the activation of the Src kinase Lck

Platinum-conjugated antibodies for application in mass cytometry

A Universal Live Cell Barcoding-Platform for Multiplexed Human Single Cell Analysis

Compensation of Signal Spillover in Suspension and Imaging Mass Cytometry

CyTOF workflow: differential discovery in high-throughput highdimensional cytometry datasets

Differential discovery in high-dimensional cytometry via high-resolution clustering

A comparison of single-cell trajectory inference methods

PAGA: graph abstraction reconciles clustering with trajectory inference through a topology preserving map of single cells

ForceAtlas2, a continuous graph layout algorithm for handy network visualization designed for the Gephi software

The authors would like to thank all participants in the study. We thank and acknowledge Takayuki Shiroyama, Kotaro Miyake, Yasuhiko Suga and Yujiro Naito for